 TEL AVIV, Israel, April 08, 2021 GLOBE NEWSWIRE -- Vascular Biogenics Ltd. VBL Therapeutics or the Company NASDAQ: VBLT, today announced that it intends to offer and sell ordinary shares and, to certain investors in lieu thereof, pre-funded warrants to purchase ordinary shares in an underwritten public offering. As part of this proposed offering, VBL Therapeutics expects to grant the underwriters a 30-day option to purchase up to an additional 15 of the aggregate number of ordinary shares plus the ordinary shares underlying any pre-funded warrants that are sold in the offering, at the public offering price less the underwriting discounts and commissions. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the securities in the offering are to be sold by VBL Therapeutics. 